Dr. David Solomon is a Clinical Associate Professor in the Department of Psychiatry and Human Behavior in the Brown University School of Medicine. Dr. Solomon has served as the principal investigator or co-investigator for many studies, and has reviewed grant proposals for the National Institute of Mental Health, National Alliance for Research in Schizophrenia and Affective Disorders, as well as practice guidelines and task force reports for the American Psychiatric Association.

Dr. David Solomon is a Clinical Associate Professor in the Department of Psychiatry and Human Behavior in the Brown University School of Medicine. He is the Assistant Director of the Mood Disorders Program at Rhode Island Hospital, and is also the Assistant Director of the Inpatient Unit and the Director of the Electroconvulsive Therapy Program. His primary area of research is the course of illness and treatment of mood disorders such as bipolar disorder and major depressive disorder. Dr. Solomon has served as the principal investigator, co-investigator, or investigator for many studies, and has reviewed grant proposals for the National Institute of Mental Health, National Alliance for Research in Schizophrenia and Affective Disorders, as well as practice guidelines and task force reports for the American Psychiatric Association. He is an ad hoc editor for several medical journals and has authored more than 60 peer-reviewed articles. In addition, Dr. Solomon has received awards from the Brown University School of Medicine and the American Psychiatric Association in recognition of his teaching activities.

1. Principal Investigator, "Valproate in Combination with Lithium Carbonate
for the Maintenance Treatment of Bipolar Patients at High Risk for
Recurrence," Young Investigator Award, 1992-94, National Alliance for
Research on Schizophrenia and Depression, $60,000

2. Co-Principal Investigator, "Valproate in Combination with Lithium
Carbonate for the Maintenance Treatment of Bipolar Patients at High Risk for
Recurrence," 1992-94, Abbott Laboratories, $10,000

3. Investigator, "Family Treatment of Bipolar Disorder," R01 MH48171, Ivan
Miller, Principal Investigator, 9/1/92-2/28/99, National Institute of Mental
Health, $2,196,753

4. Investigator, "A Phase II, Multicenter, Randomized, Parallel-Group, Double-
Blind, Dose-Finding Study of 3 Different Doses of Roxindole vs. Placebo in
Outpatients with Major Depression," Martin B. Keller, Principal Investigator,
6/93-7/94, EM Industries, $93,492

5. Investigator, "Double-Blind Parallel Comparison of Sertraline and
Imipramine in Outpatients with Chronic Major Depression," Martin B.
Keller, Principal Investigator, 4/1/93-3/30/97, Pfizer, $600,000

6. Investigator, "Double-blind Parallel Comparison of Sertraline and
Imipramine in Outpatients with Concurrent DSM-III-R Major Depression
and Dysthymia," Martin B. Keller, Principal Investigator, 4/1/93-3/30/97,
Pfizer, $600,000

7. Investigator, "Fluoxetine vs. Sertraline and Paroxetine in Major Depression:
Comparison of Discontinuation/Emergent Signs and Symptoms," Gabor
Keitner, Principal Investigator, 9/1/96-9/1/97, Eli Lilly, $146,973

8. Investigator, "A Multi-Center Study Comparing the Safety and Efficacy of
Nefazodone HCl to Cognitive Behavioral Therapy – Chronic Depression
(CBT-CD) and Combined Nefazodone HCl and CBT-CD for the Acute,
Continuation, and Maintenance Treatment of Chronic Forms of Depression,"
Martin B. Keller, Principal Investigator, 6/1/96-5/31/99, Bristol Myers Squibb,
$798,000

9. Investigator, "Thyroxine Treatment of the Neurocognitive Side Effects of
Lithium," Independent Investigator Award, Robert Stern, Principal
Investigator, 1997-99, National Alliance for Research on Schizophrenia and
Depression, $92,592

10. Investigator, "Multicenter, Placebo-Controlled Study of Relapse Prevention by
Long-Term Treatment with Remeron in Outpatients with Major Depressive
Episode," Martin B. Keller, Principal Investigator, 9/97-3/99, Organon,
$217,000

11. Principal Investigator, "Lithium plus Valproate for Treatment of Bipolar
Disorder," Department Research Award, 1998-99, Department of Psychiatry
and Human Behavior, Brown University, $11,583

12. Investigator, "Olanzapine versus Placebo in the Treatment of Bipolar
Disorder, Manic or Mixed," Gabor Keitner, Principal Investigator, 2/98-6/99,
Eli Lilly, $279,187

13. Investigator, "Efficacy of a Family Telephone Intervention for Stroke," R01
NS37840, Ivan Miller, Principal Investigator, 9/1/98-8/30/03, National Institute of Neurological Disorders and Stroke, $2,540,523

14. Investigator, "An Eight Week, Multicenter, Parallel-Group, Double-Blind,
Placebo-Controlled Study of St. John's Wort in Outpatients with DSM-IV
Major Depression," Martin B. Keller, Principal Investigator, 9/1/98-8/31/99, Vanderbilt University and Pfizer, $138,300

15. Investigator, "Open Trial of St. John's Wort in the Treatment of Subsyndromal Depression," Ivan Miller, Principal Investigator, 1998-1999, Lifespan, $10,000

16. Investigator, "Integrative Group Treatment for Depression," R21 MH59791 Ivan Miller, Principal Investigator, 4/99-3/02, NIMH, $298,084

17. Investigator, "An Open-Label Randomized Assessment of the Efficacy and
Tolerability Venlafaxine Extended Release in Serotonin-Selective Reuptake
Inhibitor (SSRI) Failure Patients with Major Depression," Gabor Keitner,
Principal Investigator, 6/99-6/00, Wyeth-Ayerst Laboratories, $87,000

18. Investigator, "A Double-Blind Study of Two Doses of LL-759274 versus
Paroxetine Hydrochloride and Placebo in the Treatment of Outpatients with
Major Depressive Disorder," Gabor Keitner, Principal Investigator, 6/99-6/00,
Merck & Co., $221,000

19. Investigator, "Antidepressant Treatment to Reduce HIV Risk Among Injection Drug Users," R01 MH61141, Michael Stein, Principal Investigator, 9/30/99-8/31/03, NIMH $1,169,268

20. Investigator, "The Use of Mirtazapine in Reducing SSRI-Induced Sexual Side
Effects," Gabor Keitner, Principal Investigator, 3/1/00 –current, Yale
University and Organon, $198,000

21. Investigator, "Clinical Trial of Donepezil HCl (Aricept) in Diminishing
Cognitive Impairment Associated with Electroconvulsive Therapy," Robert A. Stern, Principal Investigator, 7/1/00-6/30/02, Pfizer, $136,068

22. Investigator, "Combined Treatment for Depressed Inpatients," R01 MH58866, Ivan Miller, Principal Investigator, 2/15/00-3/1/05, NIMH, $3,289,792

23. Co-investigator, "Antidepressant Treatment to Reduce HIV Risk Among Injection Drug Users," R01 MH61141, Michael Stein, Principal Investigator, 9/28/99-9/27/03, NIMH $1,815,221

24. Co-investigator, "Antidepressant Treatment to Maintain Risk Reduction Among Injection Drug Users," R01 MH62719, Michael Stein, Principal Investigator, 9/30/00-8/31/05, NIMH $2,284,149

25. Co-Principal Investigator, "Collaborative Depression Study," 2R10
MH25478-24, Martin Keller, Principal Investigator, 7/1/98-6/30/03, National
Institute of Mental Health

26. Co-Principal Investigator, "Collaborative Depression Study (no cost extension),"
2R10 MH25478-29, Martin Keller, Principal Investigator, 7/1/03-6/30/04,
National Institute of Mental Health

27. Co-Principal Investigator, "Collaborative Depression Study," 2R10
MH25478-29A2, Martin Keller, Principal Investigator, 7/1/04-6/30/09, National
Institute of Mental Health

National Research Service Award, National Institute on Drug
Abuse and National Institute on Alcohol Abuse and Alcoholism, 1990-91

New Investigator Award, New Clinical Drug Evaluation Unit,
National Institute of Mental Health, 1995

American Psychiatric Association, Committee on Medical
Student Education, Tenth Annual Nancy C.A. Roeske, M.D.,
Certificate of Recognition for Excellence in Medical Student
Education, 2000

Outstanding Teaching Award in Adult Psychiatry, Department
of Psychiatry and Human Behavior, Brown University School of
Medicine, 1999-2000

Dean's Teaching Excellence Award,
Brown University School of Medicine, 2001

Massachusetts Medical Society, 1983-present

American Psychiatric Association, 1984-present

Rhode Island Psychiatric Society, 1990-present

American Medical Association, 1990-present